Builds value by sourcing, financing and enhancing minority stakes in technology companies, concentrated in medical devices and pharmaceuticals, and intends to earn by realising those holdings through sale to third parties or public offerings; income in the year came from fair-value gains, dividends and finance income rather than from sales.
